![]() |
Name |
diaporthsin A
|
Molecular Formula | C10H16O3 | |
IUPAC Name* |
4-hydroxy-2-methyl-2,3,4,5,8,9-hexahydrooxecin-10-one
|
|
SMILES |
CC1CC(O)CC=CCCC(=O)O1
|
|
InChI |
InChI=1S/C10H16O3/c1-8-7-9(11)5-3-2-4-6-10(12)13-8/h2-3,8-9,11H,4-7H2,1H3/b3-2+/t8-,9+/m1/s1
|
|
InChIKey |
OZVQGKLKHXNYBY-ALCGYSGWSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 184.23 | ALogp: | 1.4 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 46.5 | Aromatic Rings: | 1 |
Heavy Atoms: | 13 | QED Weighted: | 0.462 |
Caco-2 Permeability: | -4.449 | MDCK Permeability: | 0.00081790 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.013 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.002 |
30% Bioavailability (F30%): | 0.94 |
Blood-Brain-Barrier Penetration (BBB): | 0.789 | Plasma Protein Binding (PPB): | 37.33% |
Volume Distribution (VD): | 1.354 | Fu: | 55.60% |
CYP1A2-inhibitor: | 0.091 | CYP1A2-substrate: | 0.102 |
CYP2C19-inhibitor: | 0.021 | CYP2C19-substrate: | 0.326 |
CYP2C9-inhibitor: | 0.007 | CYP2C9-substrate: | 0.819 |
CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.173 |
CYP3A4-inhibitor: | 0.065 | CYP3A4-substrate: | 0.21 |
Clearance (CL): | 13.25 | Half-life (T1/2): | 0.848 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.06 |
Drug-inuced Liver Injury (DILI): | 0.028 | AMES Toxicity: | 0.016 |
Rat Oral Acute Toxicity: | 0.007 | Maximum Recommended Daily Dose: | 0.712 |
Skin Sensitization: | 0.945 | Carcinogencity: | 0.929 |
Eye Corrosion: | 0.932 | Eye Irritation: | 0.921 |
Respiratory Toxicity: | 0.059 |